Life-saving diagnostic equipment needed for prevention and screening of prostate cancer.

A man dies every 19 moments from prostate cancer, though prostate cancer could be cured when detected early even. Existing prostate diagnostics, such as the PSA biomarker and digital rectal test, cause widespread underdiagnosis, overtreatment and overdiagnosis, with dire human being and societal costs, Dr. Shtern stated. Current diagnostics miss and/or underestimate the level or aggressiveness of prostate cancer and result in treatment failures in as much as half of most men. False diagnostic alarms create a staggering extent of needless biopsies and treatment, costing billions of dollars each year.and Abbott today announced that Sucampo Pharma, Ltd. Related StoriesScripps Florida scientists win $2.4 million to expand development of new suffering therapies ‘We are very pleased to receive Japan’s first-ever acceptance for a prescription drugs for chronic constipation since it helps us achieve our objective of bringing medications with novel mechanisms of action to sufferers with unmet medical requirements on a global basis,’ said Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman and Chief Executive Officer.